| 查看: 3934 | 回复: 17 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
【招聘】清华大学药学院钱锋教授课题组诚聘博士后
已经有1人回复
-
新版scifinder
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有282人回复
-
安捷伦液相色谱柱与方法开发指南
已经有4人回复
-
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复
-
中国医药行业发展现状：标准品推动药品检测水平提升
已经有1人回复
-
标准品的纯度对于药品质量的影响有多大？
已经有0人回复
-
如何制备符合技术要求的药品标准品？
已经有0人回复
-
对照品在药品研发中的不可或缺性
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
【招聘】温州医科大学/附属医院/瓯江实验室李校堃院士团队诚聘博士后和科研人员
+1/192
-
三峡大学材料与化工学院环境功能材料课题组招生硕士调剂生
+1/160
-
希望面上好运
+2/108
-
上海高校招收化学，材料，环境，化工等专业基础的同学攻读硕士研究生
+1/82
-
赣南师范大学肖兴教授课题组招2026级电子信息硕士 4-6 名，欢迎调剂
+1/82
-
中飞院航空锂电池团队接受硕士生调剂
+1/74
-
资源与环境专硕
+1/73
-
中原食品实验室 & 郑州轻工业大学2026年硕士研究生联合培养调剂公告
+1/39
-
招收2026级环境科学方向（专业代码083001）硕士研究生1-2名
+1/37
-
招收材料、化学类调剂生，专硕学硕均可
+1/33
-
欢迎08开头或部分07开头的有缘人报考
+1/33
-
中国科学院上海硅酸盐研究所施剑林院士团队胡萍课题组招聘博士后
+1/14
-
08工学英一数二290 三个奖学金两个省三 一个省创优秀结项 B区求调剂
+1/14
-
南京医科大学-谭磊课题组-诚招博士后
+1/10
-
诚聘博士科研人员（有机合成化学方向）
+1/8
-
欢迎来英国拉夫堡大学交流-结晶，蛋白质，AI，水处理等
+1/7
-
26博士申请
+1/5
-
半导体光电子器件与集成
+1/4
-
山东济南省属重点高校，生态环境类硕士招生 调剂 信息
+1/4
-
5科大招收材料专业硕士
+1/3
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
williamxiang: 金币+4 2013-04-03 13:01:31
|
Threats Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011 The drug may not gain approval in ACS given concerns about bleeding If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery |
5楼2013-04-03 10:54:50
